Find a Doctor
Jingsong Zhang, MD, PhD
Specialty: Medical Oncology
Program: Genitourinary Oncology
Call 1-888-MOFFITT
(1-888-663-3488)
Call 1-888-MOFFITT
(1-888-663-3488)
Locations: Moffitt Cancer Center
Moffitt Cancer Center at International Plaza
Cancer Types Treated: Prostate Cancer , Testicular Cancer , Bladder Cancer , Kidney (Renal Cell) Cancer
Dr. Jingsong Zhang is a genitourinary oncologist at Moffitt Cancer Center and an assistant professor of oncology and internal medicine at the University of South Florida College of Medicine. His primary interest is in developing new treatments for prostate cancer. As a member of the Moffitt experimental therapeutics program, Dr. Zhang is researching novel agents that might inhibit the repair pathway that allows cancer cells to survive despite DNA damaging chemotherapy treatment. He is a principal investigator in an American Society of Clinical Oncology grant to target DNA damage repair pathways in metastatic prostate cancer. Dr. Zhang received his medical degree from Peking Union Medical College in China, followed by a Ph.D. in pathology from the University of Southern California. He served as a post-doctoral research fellow at Children’s Hospital Los Angeles, before pursuing a residency in internal medicine at New York Downtown Hospital and fellowship in hematology/oncology at University of Michigan Comprehensive Cancer Center. Dr. Zhang has been published in numerous medical journals and is board certified in both medical oncology and internal medicine. He is fluent in English and Chinese.
Education & Training
Board Certification:
- Medical Oncology
Fellowship:
- University of Michigan Comprehensive Cancer Center - Hematology-Oncology
Residency:
- New York Downtown Hospital - Internal Medicine
Medical School:
- Peking Union Medical College - MD
CLINICAL TRIAL 17981
A Pilot Study of Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
Condition: Genitourinary
Intervention: Abiraterone acetate; Zytiga (Abiraterone acetate)
Open
CLINICAL TRIAL 18788
A Phase 2 Study of Check Point Inhibitor, Durvalumab (MEDI4736) for Bacillus Calmette-Guérin (BCG) Refractory Urothelial Carcinoma in Situ (CIS) of the Bladder
Condition: Genitourinary
Intervention: AMP-514 (Durvalumab); Durvalumab; MEDI4736 (Durvalumab)
Open
CLINICAL TRIAL 18986
TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency.
Condition: Genitourinary
Intervention: AG-014447 (Rucaparib); CO-338 (Rucaparib); PF-01367338-BW (Rucaparib); Rucaparib
Open
CLINICAL TRIAL 17773
A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4
Condition: Genitourinary
Intervention: ASG-22CE
Open
CLINICAL TRIAL 19363
A Single-Arm, Open-Label, Multicenter Study Of Enfortumab Vedotin (ASG-22CE) For Treatment Of Patients With Locally Advanced Or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy.
Condition: Genitourinary
Intervention: Enfortumab Vedotin
Open
CLINICAL TRIAL 19137
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects
Condition: Genitourinary
Intervention: Abiraterone acetate; Olaparib (Lynparza); Zytiga (Abiraterone acetate); prednisone
Open
CLINICAL TRIAL 19367
A Pilot Study Of Intermittent Androgen Deprivation Therapy Adapted To Serum Testosterone And PSA Levels For Stage IV Castration Sensitive Prostate Cancer
Condition: Genitourinary
Intervention: ADT; Abiraterone acetate; Bicalutamide; Casodex (Bicalutamide); Zytiga (Abiraterone acetate); prednisone
Open
CLINICAL TRIAL 19580
A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 in Patients
with Advanced Solid Tumors
Condition: Multiple
Intervention: BA3011
Open
CLINICAL TRIAL 19462
An Open-Label, First-in-Human, Dose-Escalation Study to Evaluate the Safety,
Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors and Lymphomas
Condition: Multiple
Intervention: Bay 1895344
Open
CLINICAL TRIAL 19616
A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer
Condition: Genitourinary
Intervention: AMP-514 (Durvalumab); Durvalumab; MEDI4736 (Durvalumab); Olaparib (Lynparza); Placebo
Open
CLINICAL TRIAL 19697
An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination with Atezolizumab in Subjects with Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Condition: Genitourinary
Intervention: Atezolizumab (Tecentriq); INO-5401; INO-9012
Open
CLINICAL TRIAL 19840
ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
Condition: Genitourinary
Intervention: Abiraterone acetate; CPI-1205; Enzalutamide; Zytiga (Abiraterone acetate); cobicistat; prednisone
Open
CLINICAL TRIAL 19302
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an anti-LAG-3
Monoclonal Antibody, alone and in combination with an anti-PD-1 in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: Not Applicable; TSR-033; TSR-042
Open
CLINICAL TRIAL 19319
InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative study)
Condition: Genitourinary
Intervention: Ifosfamide; Not Applicable; Taxol (paclitaxel); cisplatin; paclitaxel
Open
CLINICAL TRIAL 19435
Combination of Nivolumab Immunotherapy with Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer
Condition: Genitourinary
Intervention: BMS-936558 (Nivolumab); Casodex (Bicalutamide); Lupron (leuprolide acetate); Nivolumab
Open
CLINICAL TRIAL 19228
A Phase 2, Multi-Center, Open Label Study of NIR178 in Combination with PDR001 in Patients with Selected Advanced Solid Tumors and Non-Hodgkin lymphoma
Condition: Thoracic
Intervention: NIR178; Not Applicable; PDR001 (Spartalizumab)
Open
CLINICAL TRIAL 18826
A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Condition: Genitourinary
Intervention: ALKS 4230; Pembrolizumab (Keytruda)
Open
CLINICAL TRIAL 19671
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma (RCC)
Condition: Genitourinary
Intervention: CB-839/Placebo; Cabozantinib (XL 184); Not Applicable
Open
CLINICAL TRIAL 18345
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors
Condition: Genitourinary
Intervention: MK-3475 (Keytruda); Ziv-aflibercept
Open
CLINICAL TRIAL 19491
The IRX-2 Regimen Combined with Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to Evaluate the Safety, Determine Recommended Phase 2 Dose (RP2D), and Investigate the Biologic and Clinical Activity
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); IRX-2; Nivolumab; cyclophosphamide; cytoxan (cyclophosphamide)
Open
CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-033; TSR-042
Open
CLINICAL TRIAL 19701
VISION: An International, Prospective, Open-Label, Multicenter, Randomized Phase 3 Study of 177LU-PSMA-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (MCRPC)
Condition: Genitourinary
Intervention: Lu-PSMA-617; Not Applicable
Open
CLINICAL TRIAL 19821
A Phase 3, Multi-Center, Open-Label Study to Assess the DiagNostic
Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men with Suspected Recurrence of PrOstate CanceR (CONDOR)
Condition: Genitourinary
Intervention: [18]F-DCFPyL
Open
CLINICAL TRIAL 19109
A Phase 1/2, Open-Label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab and Other Anti-Cancer Therapies in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies
Condition: Genitourinary
Intervention: Alimta (Pemetrexed); BMS-936558 (Nivolumab); Eribulin Mesylate; NKTR-214; Nab-paclitaxel (Abraxane); Nivolumab; Paraplatin (carboplatin); Pemetrexed; Taxol (paclitaxel); carboplatin; cisplatin; paclitaxel
Open
CLINICAL TRIAL 19820
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics,and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: INCB086550
Open
CLINICAL TRIAL 19874
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Condition: Genitourinary
Intervention: BMS-936558 (Nivolumab); Lirilumab; Nivolumab
Open
CLINICAL TRIAL 19851
A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination with PD-1/L1 Blockade in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer
Condition: Genitourinary
Intervention: Atezolizumab (Tecentriq); FPV-CV301; MVA-BN-CV301
Open
If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.
- Gupta S, Nordquist LT, Fleming MT, Berry WR, Zhang J, Ervin SL, Eisner JR, Baskin-Bey ES, Shore ND. Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer. Clin Cancer Res. 2018 Nov;24(21):5225-5232. Pubmedid: 30012563.
- Peyton CC, Tang D, Reich RR, Azizi M, Chipollini J, Pow-Sang JM, Manley B, Spiess PE, Poch MA, Sexton WJ, Fishman M, Zhang J, Gilbert SM. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer. JAMA Oncol. 2018 Nov;4(11):1535-1542. Pubmedid: 30178038. Pmcid: PMC6248089.
- Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S. Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer. Oncoimmunology. 2018 Jul;7(9):e1476816. Pubmedid: 30228944. Pmcid: PMC6140546.
- Nerlakanti N, Yao J, Nguyen DT, Patel AK, Eroshkin AM, Lawrence HR, Ayaz M, Kuenzi BM, Agarwal N, Chen Y, Gunawan S, Karim RM, Berndt N, Puskas J, Magliocco AM, Coppola D, Dhillon J, Zhang J, Shymalagovindarajan S, Rix U, Kim Y, Perera R, Lawrence NJ, Schonbrunn E, Mahajan K. Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer. Mol Cancer Ther. 2018 Dec;17(12):2796-2810. Pubmedid: 30242092.
- Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol. 2017 Sep;3(9):e172411. Pubmedid: 28817753. Pmcid: PMC5824288.
- Zhang J, Cunningham JJ, Brown JS, Gatenby RA. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat Commun. 2017 Nov;8(1):1816. Pubmedid: 29180633. Pmcid: PMC5703947.
- You L, Brown JS, Thuijsman F, Cunningham JJ, Gatenby RA, Zhang J, Staňková K. Spatial vs. non-spatial eco-evolutionary dynamics in a tumor growth model. J Theor Biol. 2017 Dec;435:78-97. Pubmedid: 28870617.
- Leone AR, Zargar-Shoshtari K, Diorio GJ, Sharma P, Boulware D, Gilbert SM, Powsang JM, Zhang J, Sexton WJ, Spiess PE, Poch MA. Neoadjuvant Chemotherapy in Elderly Patients With Bladder Cancer: Oncologic Outcomes From a Single Institution Experience. Clin Genitourin Cancer. 2017 Aug;15(4):e583-e589. Pubmedid: 28410909.
- Zargar-Shoshtari K, Kongnyuy M, Sharma P, Fishman MN, Gilbert SM, Poch MA, Pow-Sang JM, Spiess PE, Zhang J, Sexton WJ. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. World J Urol. 2016 Nov;34(11):1567-1573. Pubmedid: 27072536.
- Wu M, Seto E, Zhang J. E2F1 enhances glycolysis through suppressing Sirt6 transcription in cancer cells. Oncotarget. 2015 May;6(13):11252-11263. Pubmedid: 25816777. Pmcid: PMC4484454.
- Wu M, Wang X, McGregor N, Pienta K, Zhang J. Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia. Mol Pharmacol. 2014 Jun;85(6):866-876. Pubmedid: 24627085. Pmcid: PMC4014666.
- Wu M, Dickinson SI, Wang X, Zhang J. Expression and function of SIRT6 in muscle invasive urothelial carcinoma of the bladder. Int J Clin Exp Pathol. 2014;7(10):6504-6513. Pubmedid: 25400728. Pmcid: PMC4230126.
- Liu JJ, Zhang J. Sequencing systemic therapies in metastatic castration-resistant prostate cancer. Cancer Control. 2013 Jul;20(3):181-187. Pubmedid: 23811702.
- Henderson-Jackson E, Sexton W, Zhang J, Hakam A, Petrovskyy VS, Bui MM, Chuang ST. Cystic prostatic ductal adenocarcinoma: an unusual presentation and cytological diagnosis. Ann Clin Lab Sci. 2012;42(1):81-88. Pubmedid: 22371914.
- Zhang J, Lee J, Urba S, Foster J, Worden F. A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers. Cancer Invest. 2010 Nov;28(9):910-916. Pubmedid: 20590443.
- Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Ng T, Reynolds CP, Triche TJ, Sorensen PH. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res. 2007 Apr;67(7):3094-3105. Pubmedid: 17409416. Pmcid: PMC3906735.
- Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res. 2005 Jun;65(11):4633-4644. Pubmedid: 15930281.
- Zhang J, Hu S, Schofield DE, Sorensen PH, Triche TJ. Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas. Cancer Res. 2004 Sep;64(17):6026-6034. Pubmedid: 15342383.
- Tsao JL, Zhang J, Salovaara R, Li ZH, Järvinen HJ, Mecklin JP, Aaltonen LA, Shibata D. Tracing cell fates in human colorectal tumors from somatic microsatellite mutations: evidence of adenomas with stem cell architecture. Am J Pathol. 1998 Oct;153(4):1189-1200. Pubmedid: 9777950. Pmcid: PMC1853055.
- Zhang J. Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer. Asian J Androl. 16(3):401-406. Pubmedid: 24589464. Pmcid: PMC4023365.
